WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) reported financial results for the fourth quarter and full year ended December 31, 2025, citing growth in sales of its dermatology treatment YCANTH and progress in its clinical development programs.
The company reported total revenue of $35.6 million for 2025, compared with $7.6 million in 2024.
Net revenue from YCANTH reached $15.3 million in 2025, an increase of 130% from the prior year.
Dispensed applicator units for YCANTH totaled 51,296 in 2025, up 99% from 25,773 units in 2024.
The company said selling, general, and administrative expenses declined by more than 40% compared with 2024.
Verrica said it also repaid its outstanding debt during the year and expects its existing cash resources to fund operations into the first quarter of 2027.
Jayson Rieger, president and chief executive officer of Verrica, said the company focused on expanding YCANTH use while reducing expenses.
“Our focused and efficient commercial strategy allowed us to nearly double dispensed applicator units of YCANTH from the prior year while cutting selling, general and administrative expenses by over 40%,” Rieger said.
The company is also advancing VP-315, an oncolytic peptide therapy, toward a Phase 3 clinical program for basal cell carcinoma expected to begin in 2026.
Verrica said additional analysis of the therapy has shown tumor size reductions in untreated lesions.
The company also reported progress in clinical development of YCANTH for common warts.
The first patient was dosed in a Phase 3 study of the treatment in December 2025, and Verrica said it expects to begin a second Phase 3 trial in the United States and Japan in mid-2026 in partnership with Torii Pharmaceutical.
Verrica also said it reached agreement with the European Medicines Agency on a regulatory pathway that would allow the company to seek approval of YCANTH in the European Union without conducting additional clinical studies.
Verrica Pharmaceuticals develops and commercializes treatments for dermatological diseases, including skin cancers.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.